Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 10:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 248 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Rheumatoid Arthritis (RA) Clear all
Completed Phase 3 Interventional

Study of Eszopiclone Compared to Placebo on Daytime Function in Subjects With Insomnia Related to Rheumatoid Arthritis

NCT00367965
View directory record Official record
Conditions
Insomnia, Arthritis, Rheumatoid
Interventions
Eszopiclone, placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
25 Years to 64 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
38
States / cities
Huntsville, Alabama • Tucson, Arizona • Santa Maria, California + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 9, 2026, 10:39 PM EDT
Completed Phase 1 Interventional

A Study of the Safety and Pharmacokinetics of PRO283698 in Patients With Rheumatoid Arthritis

NCT00888745
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
placebo, PRO283698
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
9
States / cities
Anniston, Alabama • Orlando, Florida • Ormond Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2010 · Synced Oct 9, 2026, 10:39 PM EDT
Completed Phase 2 Interventional Results available

A Study in Participants With Rheumatoid Arthritis on Background Methotrexate Therapy

NCT01185353
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
LY3009104, Placebo, Methotrexate
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
31
States / cities
Paradise Valley, Arizona • Peoria, Arizona • Covina, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2017 · Synced Oct 9, 2026, 10:39 PM EDT
Recruiting No phase listed Observational

A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101

NCT07403188
View directory record Official record
Conditions
Refractory Lupus Nephritis, Myasthaenia Gravis, Stiff Person Syndrome, Rheumatoid Arthritis (RA), Multiple Sclerosis, Dermatomyositis, Systemic Sclerosis (SSc)
Interventions
KYV-101
Drug
Lead sponsor
Kyverna Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2041
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 9, 2026, 10:39 PM EDT
Completed No phase listed Observational

Clinically Important Changes in Rheumatoid Arthritis

NCT00056602
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years to 100 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced Oct 9, 2026, 10:39 PM EDT
Completed Phase 1 Interventional

Study of the Safety of MDX-1342 in Combination With Methotrexate in Patients With Rheumatoid Arthritis

NCT00639834
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
MDX-1342
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
11
States / cities
Peoria, Arizona • Los Angeles, California • Fort Lauderdale, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated May 22, 2013 · Synced Oct 9, 2026, 10:39 PM EDT
Completed Phase 2 Interventional

Infliximab for the Treatment of Early Rheumatoid Arthritis

NCT00006292
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Infliximab
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 9, 2026, 10:39 PM EDT
Completed Not applicable Interventional Results available

Feasibility and Acceptability of PREVAIL (PREserving Valued Activities In Life)

NCT06706999
View directory record Official record
Conditions
Rheumatoid Arthritis (RA), Arthritis, Rheumatoid (RA)
Interventions
PREVAIL model of care
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 9, 2026, 10:39 PM EDT
Completed Phase 2 Interventional Results available

A Safety and Efficacy Study of LymphoStat-B™ (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA)

NCT00071812
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Placebo, Belimumab 1 mg/kg, Belimumab 4 mg/kg, Belimumab 10 mg/kg
Drug
Lead sponsor
Human Genome Sciences Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
63
States / cities
Birmingham, Alabama • Paradise Valley, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2013 · Synced Oct 9, 2026, 10:39 PM EDT
Completed Phase 1 Interventional

Study to Evaluate SC Route of Administration of Ofatumumab in RA Patients

NCT00686868
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
placebo, ofatumumab
Other · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Anniston, Alabama • Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Oct 9, 2026, 10:39 PM EDT
Completed Phase 2 Interventional

Treating Rheumatoid Arthritis With Tripterygium Wilfordi Hook F or Sulfasalazine

NCT00062465
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
TwHF
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 9, 2026, 10:39 PM EDT
Completed No phase listed Observational

Investigating the Impact of Mode of Administration on Item Response

NCT00783991
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Depression, Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
Palo Alto, California • Smithtown, New York
Source: ClinicalTrials.gov public record
Updated Jun 6, 2013 · Synced Oct 9, 2026, 10:39 PM EDT
Active, not recruiting Phase 2 Interventional

A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)

NCT07176390
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Tulisokibart, Placebo, Methotrexate
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
16
States / cities
Glendale, Arizona • Mesa, Arizona • La Palma, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 9, 2026, 10:39 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

KickStart30: A 30-Day Intervention for Patients With Rheumatoid Arthritis (RA)

NCT03993548
View directory record Official record
Conditions
Chronic Pain, Stress, Psychological, Healthy, Rheumatoid Arthritis
Interventions
Wellness Element 1 - Exercise, Wellness Element 2 - Mindfulness, Wellness Element 3 - Sleep Hygiene, Wellness Element 4 - Social Connectedness, Wellness Element 5 - Nutrition, Wellness Element 6 - Wellness Exercises, Wellness Element 7 - Motivational Messages
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 17, 2020 · Synced Oct 9, 2026, 10:39 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH)

NCT02332590
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Sarilumab, Adalimumab, Placebo (for sarilumab), Placebo (for adalimumab)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
17
States / cities
Covina, California • Long Beach, California • Whittier, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 9, 2026, 10:39 PM EDT
Completed Not applicable Interventional

Educational Intervention to Improve Patient-Physician Awareness of Cardiovascular Risk in Rheumatoid Arthritis.

NCT03495791
View directory record Official record
Conditions
Rheumatoid Arthritis, Arthritis, Rheumatoid
Interventions
YouTube Video
Other
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 3, 2022 · Synced Oct 9, 2026, 10:39 PM EDT
Completed No phase listed Observational

The Effect of Guided Care With Vectra Compared to Treatment as Usual in Patients With Rheumatoid Arthritis

NCT03631225
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
Vectra
Diagnostic Test
Lead sponsor
Sequenom, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
30
States / cities
La Mesa, California • Murrieta, California • Orange, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 9, 2026, 10:39 PM EDT
Completed Phase 1 Interventional Results available

Co-Administration Of Methotrexate And CP-690,550

NCT01745055
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CP-690,550 (tofacitinib), Methotrexate (MTX)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
4
States / cities
Daytona Beach, Florida • Fort Lauderdale, Florida • Miramar, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Oct 9, 2026, 10:39 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease

NCT02760433
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Olokizumab, Placebo
Drug
Lead sponsor
R-Pharm International, LLC
Industry
Eligibility
18 Years and older
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
50
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Covina, California + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 9, 2026, 10:39 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Exploratory Trial to Evaluate Premature Endothelial Dysfunction in Early Rheumatoid Arthritis(RA)Compared to Patients With Established RA, and Normal Subjects

NCT01499732
View directory record Official record
Conditions
Premature Endothelial Dysfunction, Rheumatoid Arthritis, Healthy
Interventions
Not listed
Lead sponsor
Orrin M Troum, M.D. and Medical Associates
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated May 8, 2013 · Synced Oct 9, 2026, 10:39 PM EDT
Completed Phase 2 Interventional Results available

Effects of Tofacitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA)

NCT01164579
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tasocitinib plus Methotrexate, Tofacitinib plus placebo methotrexate, Placebo tofacitinib plus Methotrexate
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
8
States / cities
Gilbert, Arizona • Huntington Beach, California • Upland, California + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2015 · Synced Oct 9, 2026, 10:39 PM EDT
Not yet recruiting Not applicable Interventional

Patient-Reported Outcomes Dashboard With Goal Setting to Support Shared Decision-Making in Inflammatory Arthritis

NCT07865390
View directory record Official record
Conditions
Arthritis, Psoriatic (PsA), Arthritis, Rheumatoid (RA)
Interventions
Patient-Reported Outcomes Dashboard With Goal Setting
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 9, 2026, 10:39 PM EDT
Enrolling by invitation No phase listed Observational

CorEvitas Rheumatoid Arthritis (RA) Drug Safety & Effectiveness Registry

NCT01402661
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
CorEvitas
Network
Eligibility
18 Years and older
Enrollment
91,758 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2100
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 9, 2026, 10:39 PM EDT
Completed Phase 2 Interventional Results available

Comparison of Methotrexate (MTX) and the VIBEX™ MTX Device

NCT01618968
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
MTX
Drug
Lead sponsor
Antares Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Oct 9, 2026, 10:39 PM EDT